EARLY STAGE HER2+ BREAST CANCER RECURRENCE
HER2 Breast Cancer Returns in 1 of 4 Women
VIEW INFOGRAPHIC
 
1 in 8 U.S. women develops invasive breast cancer1 (cancer that invades tissues beyond the milk ducts and lobules of the breast)2
20%-25% of these women will have HER2+ breast cancer3
HER2+ breast cancer can be aggressive and returns in about 1 in 4 women after adjuvant treatment (following surgery) with Herceptin® (trastuzumab)4-8
HER2 (human epidermal growth factor receptor 2) is a type of protein found on the surface of healthy cells that is involved in normal cell growth9
HER2+ breast cancer cells have more HER2 receptors than normal breast cells. This causes tumor cells to grow and divide faster, increasing the risk of the cancer spreading outside of the breast9
While treatments are available specifically for HER2+ breast cancer, HER2+ tumor cells can sometimes outsmart these medications and continue to grow and spread10
"It's important that patients know recurrence happens and that there are treatment options that may prevent it. Knowledge is power."

-Breast Cancer Patient Advocacy Group Representative11
Recurrence is serious, as it can mean progression to metastatic disease (cancer that has spread to other parts of the body), but there are things you can do to help reduce your risk of recurrence.
TREATMENT OPTIONS
Despite everything you've done, your breast cancer may recur. There's a 25% chance it will.
Herceptin® (trastuzumab) has improved HER2+ breast cancer survival rates by more than 30%, but we know that HER2+ breast cancer cells can become resistant to treatment over time, possibly leading to recurrence12
Blocking more of the tumor growth pathways may be an important next step to prevent this type of cancer from outsmarting treatment and continuing to grow
Anti-HER2 extended adjuvant therapy is an option following adjuvant treatment with Herceptin® (trastuzumab), to target your cancer in a different way
Knowing your options and participating in the development of your treatment plan can help you feel more confident that you're doing everything in your power to reduce your risk of recurrence
DOWNLOAD A TREATMENT PLANNING GUIDE
There is a treatment for early-stage HER2+ breast cancer that may be able to lower your risk of recurrence after standard of care. Talk to your doctor today.
MAKING A PLAN TO REDUCE YOUR RISK
"More than anything, as a HER2+ breast cancer survivor, I worry about breast cancer recurrence. My hopes and dreams are to continue living cancer-free."

-Allison, 44, Breast Cancer Survivor13
Making a Plan to Reduce Your Risk Patients report that recurrence is always top of mind, but not all physicians address the risk proactively11
Education and information can help lessen anxiety around recurrence and help you understand what steps you should take next
Having a conversation with your healthcare team about the ways to approach reducing your risk of recurrence is a great starting point
RECURRENCE DISCUSSION GUIDE

SIGN UP TO LEARN MORE

Filling out this form won’t take too long, and the information that you’ll receive may help you learn more about lowering your risk of your HER2+ breast cancer recurring.
I am a:
Please select one or both of these options
In addition to receiving ReduceRecurrence.com communications, I would like to receive updates and information regarding other products and services from Puma Biotechnology, Inc.
All information collected will be used for sending updates only and will not be shared with third parties. For more details, see our privacy policy.
Thank you for signing up to receive communications from ReduceRecurrence.com. Tell us a bit more about yourself so that we can further personalize our communications to you.
Are you, your friend, or loved one (required):
What topics would you find most helpful?
Thank you for signing up to receive information from ReduceRecurrence.com.
Keep an eye out for communications from us.

UNITED IN SUPPORT OF YOU

This website is brought to you by Puma Biotechnology, Inc. in collaboration with the following groups:

BreastCancer.org CancerCare Living Beyond Breast Cancer - With you, for you
MyLifeLine SHARE - Dedicated experienced support for women facing breast and ovarian cancers Tigerlily Foundation - Beauty. Strength. Transformation YSC - Young Survival Coalition
We proudly support these organizations in their mission to provide education
and promote awareness among patients and the medical community.
These groups sponsor periodic web-based programs and have resources that
include additional information on approaches that may help lower your risk of
recurrence, such as maintaining a healthy weight and exercising regularly.

To learn more, please visit their websites by clicking on the logos above.
REDUCERECURRENCE.COM IS SPONSORED BY PUMA BIOTECHNOLOGY, INC.
1.Breastcancer.org. U.S. Breast Cancer Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed 10-10-17.
2.Breastcancer.org. Non-Invasive or Invasive Breast Cancer. http://www.breastcancer.org/symptoms/diagnosis/invasive. Accessed 10-10-17.
3.Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
4.Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:1-10.
5.Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685-5692.
6.Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open label, randomised controlled trial. Lancet. 2013;382:1021-1028.
7.Slamon DJ, Eiermann W, Robert NJ, et al. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients. 2015 San Antonio Breast Cancer Symposium. Abstract S5-04. Presented December 11, 2015.
8.Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.
9.Breastcancer.org. HER2 Status. http://www.breastcancer.org/symptoms/diagnosis/her2. Accessed 10-10-17.
10.National Comprehensive Cancer Network®. NCCN Guidelines for Patients® Breast Cancer Early-Stage, Version 1.2016.
11.Data on File. Puma Patient Advocacy Group Survey, 2017.
12.National Cancer Institute. A Story of Discovery: HER2’s Genetic Link to Breast Cancer Spurs Development of New Treatments. https://www.cancer.gov/research/progress/discovery/HER2. Accessed 10-10-17.
13.Data on File. 2017.